skip to content

Annual Results

4D pharma losses widen

31 March 2016 08:01

4D pharma posts a pre-tax loss of GBP10.1m for the year to the end of December - up from GBP2.4m last time.

The group raised a total of GBP64.8 million, gross, through two placings during the year and cash, cash equivalents, deposits and short-term investments increased to GBP85.4 million (2014: GBP31.8 million).

Following the period end 4D acquired Tucana Health Limited, a start-up company from University College Cork, founded to investigate the use of microbiome signatures to aid the diagnosis and treatment of diseases.

Chief executive Duncan Peyton said: "We are delighted to release our annual results for the year, which has seen the evolution of the Group's discovery projects and research methodology. We now have 15 therapeutic programmes in development covering the areas of autoimmunity, central nervous system (CNS) disorders and cancer as well as a number of candidates progressing through clinical trials. We remain excited by the prospects for the coming period."

At 8:01am: (LON:DDDD) 4d Pharma Plc Ord 0.25p share price was +2.5p at 967.5p

Story provided by

Related Company: DDDD

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.